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Abstract
Positive modulation of the GABAB receptor (GABABR) represents a potentially
useful therapeutic approach for the treatment of nicotine addiction. The posi-
tive allosteric modulators (PAMs) of GABABR GS39783 and BHF177 enhance
GABA-stimulated [35S]GTPcS-binding, and have shown efficacy in a rodent
nicotine self-administration procedure reflecting aspects of nicotine dependence.
Interestingly, the structural related analog, NVP998, had no effect on nicotine
self-administration in rats despite demonstrating similar pharmacokinetic prop-
erties. Extensive in vitro characterization of GS39783, BHF177, and NVP998
activity on GABABR-regulated signaling events, including modulation of cAMP,
intracellular calcium levels, and ERK activation, revealed that these structurally
related molecules display distinct pathway-specific signaling activities that corre-
late with the dissimilarities observed in rodent models and may be predictive of
in vivo efficacy. Furthermore, these GABABR allosteric modulators exhibit spe-
cies-dependent activity. Collectively, these data will be useful in guiding the
development of GABABR allosteric modulators that display optimal in vivo effi-
cacy in a preclinical model of nicotine dependence, and will identify those that
have the potential to lead to novel antismoking therapies.
Abbreviations
cAMP, cyclic adenosine monophosphate; CHO cells, Chinese hamster ovary cells;
CRC, concentration–response curve; ERK, Extracellular signal-regulated kinases;
GABA, c-aminobutyric acid; GPCR, G protein-coupled receptor; HEK293 cells, hu-
man embryonic kidney 293 cells; PAM, Positive allosteric modulator.
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Introduction
The GABABR is an obligate heterodimer, where
heterodimerization between the GABABR1 and GABABR2
subunits form the functional GABABR. The GABABR1
subunit contains the c-aminobutyric acid (GABA) orthos-
teric agonist binding site, whereas the GABABR2 subunit
couples to heterotrimeric Gi/0 proteins. Agonism of the
GABABR leads to a decrease in cAMP levels via inhibition
of adenylyl cyclase, increased intracellular calcium (New
et al. 2006), and phosphorylation of the extracellular-
signal regulated protein kinase 1/2 (ERK1/2) (Tu et al.
2007) (Vanhoose et al. 2002). Thus, GABABR couples to
several distinct intracellular signal transduction pathways.
Dysfunction of GABABR signaling is associated with
various disorders including epilepsy, anxiety, depression,
sleep disorders, cognitive impairment, and drug addiction
(Pinard et al. 2010). Hence, GABABR agonists, such as
baclofen, are of potential utility in the management of
such diseases. However, side effects, principally sedation,
tolerance, and motor impairment, limit their therapeutic
use.
Emerging concepts in receptor pharmacology, such as
functional selectivity and allosteric modulation, have
attracted considerable interest recently from a therapeu-
tic perspective. Functional selectivity or ligand-bias refers
to the ability of a particular ligand to activate one sig-
naling pathway to the exclusion of others suggesting that
one can fine-tune the signaling output of a target recep-
tor. Allosteric modulation arises from molecules that
bind to a site on the receptor that is topographically
distinct from the orthosteric binding site of the recep-
tor’s natural ligand (Christopoulos 2002). Allosteric
ligands modulate not only orthosteric ligand efficacy but
can also display intrinsic activity. The discovery of posi-
tive allosteric modulators (PAMs) of the GABABR, was
first reported by Urwyler et al. (2001). CGP7930 was
found to specifically act on the GABABR2 subunit, yet it
exhibited intrinsic agonist activity suggesting allosteric
communication between subunits (Binet et al. 2004). In
preclinical studies, CGP7930 in combination with baclo-
fen has shown improved therapeutic-like benefits over
baclofen alone with respect to sedation (Carai et al.
2004), depression-like (Mombereau et al. 2004), and
drug-seeking behaviors in rodents (Lhuillier et al. 2007;
Mombereau et al. 2007). High throughput screening of
small molecule libraries led to the identification of the
positive allosteric modulator N’-dicyclopentyl-2-
methylsulfanyl-5-nitro-pyrimidin-4,6-diamine (GS39783)
(Urwyler et al. 2003, 2005; Guery et al. 2007). This
chemical scaffold was led to the development of analogs
BHF177 and NVP998 which have been demonstrated to
enhance GABA-dependent GABABR activation (Guery
et al. 2007). Subsequently, it was shown that BHF177
was effective at decreasing nicotine self-administration,
supporting the potential utility of GABABR PAMs as
novel pharmacotherapies for nicotine addiction. It
should be noted here that nicotine is the main psy-
choactive ingredient in tobacco that is believed to per-
petuate the harmful tobacco smoking. Interestingly, it
was found that GS39783 could only achieve comparable
in vivo efficacy as BHF177 when co-administered with a
subeffective dose of the GABABR agonist CGP44532
(Paterson et al. 2008).
Here, we show that the structurally related GS39783/
BHF177 analog NVP998 failed to decrease nicotine
self-administration in the rat despite having similar
in vivo pharmacokinetic properties. To test whether the
dissimilarities observed in vivo could be explained by
differences in the in vitro pharmacological activity
profile of these allosteric modulators, we developed a
multiple cell-based functional assay platform to investi-
gate the effects of GS39783, BHF177, and NVP998 on
GABABR-mediated cellular responses including cAMP
production, intracellular Ca2+ mobilization, and ERK1/2
phosphorylation. The modulation of GABABR-mediated
cellular responses was investigated using both rat and
human GABABR-expressing cellular systems. Collectively,
our results reveal the existence of functional selectivity
and species-selective modulation of GABABR signaling
by these structurally related GABABR allosteric
modulators.
Materials and methods
Intravenous nicotine self-administration
Animals
Male Wistar rats (Charles River, Raleigh, NC), weighing
300–350 g at the beginning of the experiments, were
housed two per cage in an environmentally controlled
vivarium on a reversed 12 h/12 h light/dark cycle
throughout the experiment. All behavioral testing
occurred during the dark phase of the light/dark cycle.
Rats had ad libitum access to food and water initially and
were subsequently put on a food-restricted diet of 20 g
rat chow per day during behavioral training and testing.
All procedures were conducted in accordance with the
guidelines from the National Institutes of Health and the
Association for the Assessment and Accreditation of Lab-
oratory Animal Care and were approved by the Institu-
tional Animal Care and Use Committees of our
institutions.
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Apparatus
Standard operant conditioning chambers (24 9 30
9 28 cm; Med Associates, St. Albans, VT) were used in
all experiments as described previously (Liechti et al.
2007a).
Food self-administration under a fixed-ratio
schedule of reinforcement
Naive rats were gradually trained to lever press for food
(45 mg Noyes food pellets) on a fixed-ratio five timeout
20 sec (FR5 TO20 s) schedule during 1 h sessions for
3 weeks (5 days per week). After successful acquisition of
stable food self-administration, NVP998 (0, 20, 40 and
80 mg/kg, p.o.; 1 h pretreatment) was administered using
a within-subjects Latin-square design. At least 7 days
elapsed between drug administrations, and rats were
required to exhibit stable baseline performance prior to
drug administration.
Nicotine self-administration under a fixed-
ratio schedule of reinforcement
Naive rats were gradually trained to lever press for food
on an FR5 TO20 s schedule over a period of 5–7 days.
After food training, all the rats were surgically prepared
with an intravenous catheter inserted into the right jugu-
lar vein under isoflurane (1–3% in oxygen) anesthesia as
described previously (Liechti and Markou 2007b). For the
rats used for the assessment of intracerebroventricular
(i.c.v.) administration of NVP998 on nicotine self-admin-
istration, guide cannulae (26 gage; Plastics One, Roanoke,
VA) were implanted bilaterally 1 mm above the cere-
broventricular (from bregma: anterior/posterior, 0.9 mm;
medial/lateral, 1.8 mm; dorsal/ventral, 3.4 mm from
dura; angle: 10 degree) using a stereotaxic frame (David
Kopf Instruments, Tujunga, CA). After surgery, the ani-
mals were allowed to recover for at least 5 days before
nicotine self-administration training was initiated. During
nicotine self-administration training, animals self-admi-
nistered nicotine (0.03 mg/kg/infusion) on an FR5 TO20
s schedule during 1 h sessions for 4–5 weeks (5 days per
week). After successful acquisition of stable nicotine self-
administration, NVP998 (0, 20, 40, and 80 mg/kg, p.o.;
1 h pretreatment) was administered using a within-sub-
jects Latin-square design. At least 7 days elapsed between
drug administrations, and rats were required to exhibit
stable baseline performance prior to drug administration.
For the rats that were prepared with intracranial guide
cannulae, NVP998 (0, 4 and 8 lg/side, 0.5 h pretreat-
ment) was administered using a between-subjects design.
Nicotine self-administration under a
progressive-ratio schedule of reinforcement
The food training, intravenous catheterization surgery,
and nicotine self-administration training under the
fixed-ratio schedule were the same as that described in
section 2.7.4. After successful acquisition of stable nico-
tine self-administration under fixed-ratio, rats were
switched to the progressive-ratio schedule of reinforce-
ment as described previously (Paterson et al. 2008). In
this schedule, the level press numbers for a single nico-
tine infusion were progressively increased. The break-
point was defined as the highest ratio completed before
the first 1 h period during which no injections were
earned. The number of responses required to earn a
nicotine infusion on the progressive ratio was deter-
mined by the exponential progression [5e(0.25 9 (infusion
number + 3) – 5], with the first two values replaced by 5
and 10 (modified from (Richardson and Roberts 1996)),
so that the response requirements for successive rein-
forcers were 5, 10, 17, 24, 32, 42, 56, 73, 95, 124, 161,
208, etc. The effects of NVP998 (0, 20, 40 and 80 mg/
kg, p.o.; 1 h pretreatment) were assessed in animals that
showed stable nicotine self-administration behavior using
a within-subjects Latin-square design.
Pharmacokinetic procedures
To assure that differences in the self-administration tests
were not due to pharmacokinetics or CNS exposure, rats
were administered 20 mg/kg GS39783, BHF177, or
NVP998 by oral gavage and plasma levels were quanti-
tated at 0.5, 1, and 1.5 h. These times represented the
beginning, middle, and end of the self-administration
experiments where compound was administrated 30 min
prior to initiating the testing session. Brains were col-
lected at the 1.5 h time point. Plasma was generated by
standard centrifugation techniques and immediately fro-
zen. Plasma and brain were mixed with acetonitrile (1:5
v:v or 1:5 w:v, respectively). Plasma samples were vor-
texed and allowed to sit on ice for 15 min, and brain
samples were disrupted with a probe tip sonicator. Sam-
ples are centrifuged through a Millipore Multiscreen
Solvinter 0.45 micron low binding PTFE hydrophilic fil-
ter plate and drug levels were determined using an
ABSciex 5500 mass spectrometer (Framingham, MA,
U.S.A.) with multiple reaction monitoring and mass
transitions of 338.2?202.1 for GS39783, 348.2?254.2
for BHF177, and 359.2?265.2 for NVP998. Brain con-
centrations were quantitated as drug per mg tissue and
converted to a molar concentration by assuming a con-
version of 1 g tissue equals 1 mL.
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Compounds
GABA, baclofen, CGP54626, and GS39783 were purchased
from Tocris Biosciences (Avonmouth, Bristol, United
Kingdom). BHF177 and NVP998 were synthesized and
provided by Dr. M.G. Finn, Georgia Tech, GA. () Nico-
tine hydrogen tartrate (Sigma, St. Louis, MO) was dis-
solved in saline (0.9%) and pH-adjusted to 7.4 (0.5)
with 1 mol/L sodium hydroxide solution. Nicotine doses
are reported as freebase concentrations.
Cell culture
A stable CHO (Chinese hamster ovary) cell line expressing
a functional GABABR comprised of human GABABR1b and
rat GABABR2 (CHORGBR; a kind gift from Dr. K. Kaup-
mann, Novartis, Basel, Switzerland), a stable CHO cell line
expressing a functional GABABR comprised of human
GABABR1b and human GABABR2 (CHOHGBR) and a stable
HEK293 (human embryonic kidney) cell line expressing a
functional GABABR comprised of human GABABR1b and
human GABABR2 (HEKHGBR) were used for all cell-based
experiments described herein. CHORGBR, CHOHGBR, and
HEKHGBR cells were cultured in F12 medium and DMEM,
respectively, supplemented with 10% fetal bovine serum,
1 mg/mL geneticin, and 250 lg/mL zeocin.
Measurement of cAMP levels
CHORGBR and HEKHGBR cells were seeded into white-walled
384-well plates at a density of 2000 and 2500 cells per well,
respectively, in 20 lL of growth media and cultured over-
night at 37°C, 5% CO2. The following day medium was
removed and replaced with 20 lL of Hanks’ balanced salt
solution (HBSS), 20 mmol\L HEPES, pH 7.4. After 1 h
incubation at room temperature (RT), 5 lL of induction
medium (HBSS, 20 mmol\L HEPES containing forskolin;
50 lmol/L and 150 lmol/L for CHORGBR and HEKHGBR,
respectively) (MP biochemical, Irvine, CA 92618 USA), and
the test compounds together with GABA were added to the
cells at the indicated concentrations. After 10 min and
20 min incubations at RT for the CHORGBR and the
HEKHGBR cells, respectively, cAMP levels were measured
using Cisbio’ (Bedford, MA 01730 USA) cAMP dynamic
HTRF assay kit as per the manufacturer’s instructions.
Briefly, induction medium was removed and the cells were
lysed in 10 lL of 1:1 PBS-lysis buffer containing cAMP
labeled with the acceptor dye d2. Subsequently, 10 lL of 1:1
PBS-lysis buffer containing cAMP-specific antibody labeled
with cryptate was added to each well. After 1 h at room tem-
perature, the amount of cAMP in lysate samples was quanti-
fied according to the manufacturer’s instructions using the
Envision plate reader (PerkinElmer, Shelton, CT 06484-4794
USA). Concentration–response curves (CRC) were recorded
with four wells per concentration and experiment. The
effects of the compounds were calculated relative to the
stimulation obtained with a maximally active concentration
of GABA. CRCs were determined by nonlinear regression
analysis using Prism software (GraphPad Software Inc., San
Diego, CA).
Measurement of intracellular calcium
concentration
CHORGBR and HEKHGBR cells were seeded into black-walled
384-well plates at a density of 10,000 and 20,000 cells per well,
respectively, in 20 lL of growth media and cultured overnight
at 37°C, 5% CO2. The following day the medium was removed
and replaced with 20 lL of loading medium consisting of
HBSS, 20 mmol/L HEPES, 2.5 mmol/L probenicid, and fluo-
rescent indicator Fluo-4 AM (Invitrogen, Carlsbad, CA 92008
USA). After 1 h incubation, cell and compound plates were
placed into the fluorescence imaging plate reader (FLIPR;
Molecular Devices, Sunnyvale, CA 94089 USA). Compounds
(prepared as 59 solution in HBSS and 20 mmol/L HEPES,
pH 7.4) were added at time = 10 sec and changes in fluores-
cence were monitored over a period of 250 sec following
excitation at a wavelength of 488 nm and detection at 510–
560 nm. Relative changes over baseline (ΔF/F) were deter-
mined. Concentration–response curves were recorded with
four wells per concentration and experiment. The effects of
compounds were calculated relative to the stimulation
obtained with a maximally active concentration of GABA.
CRCs were determined by nonlinear regression analysis using
Prism software (GraphPad Software Inc., San Diego, CA).
In cell ERK1/2 phosphorylation Western blot
To determine the time point at which maximum ERK1/2
phosphorylation occurs after GABABR activation,
CHORGBR and HEKHGBR cells were seeded at 5000 cells/
well in a 384-well plate and incubated overnight at 37°C,
5% CO2. The next day the medium was removed and
replaced with 20 lL of HBSS, 20 mmol/L HEPES. After
1 h incubation at 37°C, 5% CO2, 5 lL of HBSS 20 mmol/L
HEPES containing GABA was added to the plate and incu-
bated at room temperature for the indicated time periods.
After incubation, the medium was discarded and the cells
were fixed in 4% paraformaldehyde in PBS for 20 min.
Cells were then washed 39 with PBS. After discarding the
last wash, cells were permeabilized for 20 min with 0.2%
Triton X-100 in PBS then washed 39 in PBS. After discard-
ing the last wash, Odyssey blocking buffer was added and
the plate was rocked for 1 h at room temperature. Odyssey
blocking buffer was then removed, and rabbit anti-phos-
pho-ERK (1/150 in Odyssey blocking buffer) and mouse
2017 | Vol. 5 | Iss. 2 | e00288
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anti-ERK (1/200 in Odyssey blocking buffer) were added to
the plate and incubated overnight at 4°C. The following
day the plates were washed three times with 0.1% Tween 20
in PBS. Infrared probe-labeled goat-anti-mouse and anti-
rabbit (1/200 in 0.025% Tween 20 in PBS) were added. The
plates were incubated for 1 h at room temperature, washed
with 0.025% Tween 20, and scanned by the Odyssey infra-
red scanner. Data were acquired using the scanner software,
and analyzed using Prism software (GraphPad Software
Inc., San Diego, CA).
Measurement of ERK1/2 phosphorylation
CHORGBR and HEKHGBR cells were seeded at 4000 cells/
well in a 384-well plate and incubated overnight at 37°C,
5% CO2. The following day medium was removed and
replaced with 20 lL of HBSS, 20 mmol/L HEPES, pH
7.4. After 1 h incubation, 5 lL of HBSS, 20 mmol/L
HEPES containing GABA in the presence or absence of
test compounds was added to the wells and incubated at
room temperature for 5 min. After incubation, the med-
ium was discarded and the cells were lysed in 16 Μl lysis
buffer provided in the Cellul’erk HTRF cell-based assay
(Cisbio). After 10 min of incubation, 4 lL of detection
buffer containing the HTRF conjugates was added in each
well. After 2 h at room temperature, the amount of phos-
pho-ERK in the lysate samples was quantified according
to the manufacturer’s instruction using the Envision plate
reader (PerkinElmer). Concentration–response curves
were recorded with four wells per concentration and
experiment. The effects of compounds were calculated rel-
ative to the stimulation obtained with a maximally active
concentration of GABA. CRCs were determined by non-
linear regression analysis using Prism software (GraphPad
Software Inc., San Diego, CA).
Measurement of Cellular Impedance
Impedance measurements were performed using the
CellKey system (Molecular Devices). CHORGBR cells
were seeded at a density of 30,000 cells/well into
CellKey microplates (MDS SCIEX) in 100 lL of growth
medium and cultured overnight. The following day,
cells were washed three times with assay buffer (HBSS
containing 20 mmol/L HEPES, pH 7.4) and allowed to
equilibrate for 30 min. After a 90 sec read to establish
a baseline, ligands (59 in assay buffer) were added
online in the CellKey instrument and the changes of
cellular impedance were measured over 10 min. For the
desensitization assay, cells were incubated with GABA
or the PAMs for 20 min. Subsequently, the cells were
washed three times with assay buffer to remove the
ligand and allowed to equilibrate in assay buffer for
30 min before being stimulated a second time with a
fixed concentration of GABA at an EC90 (59 in assay
buffer). The changes of cellular impedance induced by
a second addition were measured over 10 min. The
effects of GABA and the PAMs were calculated relative
to the stimulation obtained with a maximally active
concentration of GABA. CRCs were determined by
nonlinear regression analysis using Prism software
(GraphPad Software Inc., San Diego, CA).
Results
Effects of NVP998 on nicotine self-
administration
The plasma concentrations of GS39783, BHF177, and
NVP998, in rats treated with 20 mg/kg of each of the
three compounds were 482  83 ng/mL (1.4 
0.2 lmol/L), 125  3 ng/mL (0.4  0.008 lmol/L), and
407  210 ng/mL (1.1  0.6 lmol/L) at the beginning
of the experiment (concentration at 1 h) and
472  16 ng/mL (1.4  0.04 lmol/L), 145  13 ng/mL
(0.4  0.03 lmol/L), and 284  176 ng/mL (0.8  0.5
lmol/L) after testing (concentration at 2 h), respectively
(Table 1). The corresponding brain concentrations of
GS39783, BHF177, and NVP998, were 635  114 ng/
mL (1.9 lmol/L), 979  80 ng/mL (2.8 lmol/L), and
321  147 ng/mL (0.9 lmol/L), respectively, (Table 1).
These data indicate that the GABABR allosteric ligands
displayed low micromolar plasma and brain concentra-
tion during testing. However, in contrast to BHF177
Table 1. Plasma and brain concentrations of NVP998, BHF177, and GS39783, before and at the end of the experiment in rat.
Drug Route
Dose
(mg/kg1)
Plasma exposure Brain exposure
Conc. 0.5 h Conc. 1 h Conc. 2 h Conc. 2 h
ng/mL lmol/L ng/mL lmol/L ng/mL lmol/L lmol/L ng/mL lmol/L lmol/L
GS39783 p.o. 20 500  67 1.5  0.2 482  83 1.4  0.2 472  16 1.4  0.04 635  114 1.9  0.3
BHF177 p.o. 20 76  44 0.2  0.1 125  3 0.4  0.008 145  13 0.4  0.03 979  80 2.8  0.2
NVP998 p.o. 20 425  184 1.2  0.5 407  210 1.1  0.6 284  176 0.8  0.5 321  147 0.9  0.4
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(20 mg/kg p.o) that significantly decreased nicotine
self-administration in rats (Paterson et al. 2008), sys-
temic administration of NVP998 (20, 40 and 80 mg/kg,
p.o.) did not affect nicotine self-administration under a
fixed-ratio or a progressive-ratio schedule of reinforce-
ment (Fig. 1A and B). The lack of effects of systemic
NVP998 on nicotine self-administration might be due
to poor brain exposure because this compound had the
lowest brain concentration among these three PAMs.
However, this possibility was excluded because i.c.v.
administration of NVP998 also had no effect on nico-
tine self-administration (Fig. 1C). Thus, we hypothesized
that the differences in drug responsiveness may result
from differences in the intrinsic properties of the com-
pound that are not observed using traditional GTPcS-
binding assays. Therefore, we further investigated the
effect of the allosteric ligands on GABABR-mediated,
changes in intracellular cAMP levels, intracellular
[Ca2+], and ERK1/2 phosphorylation.
Effects of GS39783 and analogs on GABABR-
mediated inhibition of cAMP production
Upon GABA binding, GABABR preferentially couples to
the Gai pathway, inhibiting adenylyl cyclase activity, and
thus decreasing the level of intracellular cAMP. Therefore,
we first determined the effects of GS39783, BHF177, and
NVP998 on GABA-mediated inhibition of forskolin
(FSK)-stimulated cAMP production using a CHO cell line
expressing a functional GABABR comprised of human
GABABR1b and rat GABABR2 (CHORGBR), or stable
HEK293 and CHO cell lines expressing a functional
GABABR comprised of human GABABR1b and human
GABABR2 (HEKHGBR and CHOHGBR, respectively). As
expected, the addition of GABA resulted in a concentra-
tion-dependent inhibition of FSK-stimulated cAMP pro-
duction with an EC50 value of 0.67 lmol/L, 0.52 lmol/L,
and 0.99 lmol/L in CHORGBR, HEKHGBR, and CHOHGBR
cells, respectively (Figs. 2–4). The inhibition of cAMP
Figure 1. Effects of the GABABR-positive allosteric modulator NVP998, on nicotine self-administration in rats. Systemic administration of NVP998
(20, 40 and 80 mg/kg) had no effect on nicotine or food self-administration under fixed- or progressive-ratio schedules of reinforcement in rats.
Similar lack of effect was also observed after i.c.v. administration of NVP998 (4 and 8 lg/side).
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formation by GABA was fully antagonized by the compet-
itive antagonist CGP54626, and no effect of GABA was
observed in nontransfected CHO or HEK293 cells (data
not shown).
Co-addition of 0.1–1 lmol/L of GS39783, resulted in a
twofold leftward potency shift in GABA EC50 in the
CHORGBR cells, and 5–10 lmol/L enhanced GABA EC50
~3–6 fold (Fig. 2A, Table 2). We have assigned the
potency shift observed in the presence of an allosteric
modulator an ‘a’ value, where an a value >1 defines posi-
tive modulation, and an ‘a’ value <-1 defines negative
modulation. Hence, in CHORGBR cells, 10 lmol/L
GS39783 has an a = 6 (Table 2). In HEKHGBR and
CHORGBR cells, 0.1–1 lmol/L and 5–10 lmol/L of
GS39783 generated a values of ~2–3 and ~7–9, respec-
tively (Fig. 2B and C; Table 2). Furthermore, GS39783
also exhibited significant intrinsic activity (~30% of
GABA ECmax) in CHORGBR, HEKHGBR, and CHOHGBR
cells when present at 0.5–10 lmol/L (Fig. 2A and B;
Table 2). Correlation plots constructed from the fold shift
of the GABA EC50 (a) in the presence of a given concen-
tration of the modulator demonstrated that with regard
to cAMP production, GS39783 exhibits similar PAM
activity in cellular systems expressing either the rat or the
human GABABR heterodimer (Fig. 2D, Table 3). Impor-
tantly, low micromolar concentration (0–1 lmol/L)
showed significant PAM activity with P = 0.0018, 0.0023,
and 0.0015 (F-test from nonzero slope) in CHORGBR,
CHOHGBR, and HEKHGBR, respectively (Fig. 2D, Table 3).
These results are in good agreement with GS39783 phar-
macokinetics (Table 1) and in vivo efficacy (Paterson
et al. 2008).
We next evaluated BHF177 in the CHORGBR cells. Sub-
micromolar concentration (0.1–1 lmol/L) of BHF177
enhanced GABA potency by 2–3 fold (a = 2–3), whereas
5 lmol/L and 10 lmol/L generated a values of 5–6
(Fig. 3A, Table 2). In addition, BHF177 displayed signifi-
cant intrinsic activity even at low micromolar concentra-
tions and behaved almost as a full agonist when present
at 10 lmol/L, activating the GABABR by ~80% of GABA
ECmax (Fig. 3A, Table 2). In contrast, in HEKHGBR and
CHOHGBR cells, BHF177 neither modulated nor pro-
moted GABABR activity when present at 0.1–1 lmol/L
(Fig. 3B and C, Table 2). Nevertheless, PAM activity
Figure 2. cAMP HTRF-measured effects of GS39783 on GABA-induced GABABR-mediated inhibition of forskolin-stimulated cAMP production.
Concentration–response curves for GABA in the absence and in the presence of increasing concentration of allosteric ligand in CHORGBR (A),
HEKHGBR (B), or CHOHGBR (C) cells line. (D) Linear regression plots were constructed from the logarithm of GS39783 concentration against the
logarithm of the fold shift of the GABA EC50 (a). The solid and dashed trendlines were created by plotting the a values obtained with GS39783
at 0.1–1 lmol/L or 0.1–10 lmol/L, respectively. The data are means  SEM of a typical experiment that was performed three times.
ª 2017 The Authors. Pharmacology Research & Perspectives published by John Wiley & Sons Ltd,
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(a = 3–4) and significant intrinsic activity was observed
at 10 lmol/L (Fig. 3B and C, Table 2). In addition,
BHF177 at 10 lmol/L was found to significantly increase
GABA efficacy to ~125% in HEKHGBR (Fig. 3B; Table 2).
Correlation plots constructed from the fold shift of the
GABA EC50 (a) in the presence of a given concentration
of the modulator demonstrated that low micromolar con-
centration exhibit significant PAM activity with
P = 0.0001 (F-test from nonzero slope) in cells expressing
the rat receptor (CHORGBR) (Fig. 3D, Table 3). These
in vitro data are in good agreement with BHF177 phar-
macokinetics (Table 1) and in vivo efficacy (Paterson
et al. 2008). Interestingly, similar concentrations of
BHF177 did not display PAM activity in cellular systems
expressing the human receptor (HEKHGBR and CHOHGBR)
suggesting that BHF177 might exhibit a distinct in vitro
pharmacological profile depending on the composition of
the GABABR heterodimer.
NVP998 exhibited PAM activity (a=3) and displayed
intrinsic activity (41  4%) when present at the higher
concentration (10 lmol/L) in the CHORGBR cells
(Fig. 4A, Table 2). In contrast, low micromolar concen-
trations of this allosteric ligand (0.1–5 lmol/L) failed to
enhance GABA EC50 or to activate the receptor in this
cellular system (Fig. 4A and D, Table 2). These in vitro
observations are in good agreement with the absence of
an in vivo effect of NVP998 on nicotine self-administra-
tion (Fig. 1). However, in HEKHGBR and in CHOHGBR
cells, NVP998 significantly enhanced GABA potency even
when present at low micromolar concentration with
P = 0.040 and 0.009 (F-test from nonzero slope), respec-
tively (Fig. 4B–D, Table 3). Furthermore, in these cellular
systems, 5 and 10 lmol/L of NVP998 displayed signifi-
cant agonist activity (Table 2). Thus, as previously
observed with BHF177, NVP998 exhibits system-depen-
dent ago-PAM activity.
Although, these data confirm that GS39783, BHF177,
and NVP998 display PAM activity at the GABABR; they
also reveal the existence of cellular system-dependent
effects suggesting that GABABR allosteric ligands might
exhibit species selectivity. Interestingly, although NVP998
and BHF177 both display species selectivity, they do so in
Figure 3. cAMP HTRF-measured effects of BHF177 on GABA-induced GABABR-mediated inhibition of forskolin-stimulated cAMP production.
Concentration–response curves for GABA in the absence and in the presence of increasing concentration of allosteric ligand in CHORGBR (A),
HEKHGBR (B), or CHOHGBR (C) cells line. (D) Linear regression plots were constructed from the logarithm of BHF177 concentration against the
logarithm of the fold shift of the GABA EC50 (a). The solid and dashed trendlines were created by plotting the a values obtained with BHF177 at
0.1–1 lmol/L or 0.1–10 lmol/L, respectively. The data are means  SEM of a typical experiment that was performed three times.
2017 | Vol. 5 | Iss. 2 | e00288
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favor of different species; NVP998 exhibiting increased
PAM activity at the human receptor, whereas BHF177
exhibited significant PAM activity at the rat receptor
(Fig 3D and 4D).
Effects of GS39783 and analogs on GABABR-
mediated mobilization of intracellular Ca2+
Previous reports have demonstrated that the GABABR can
promote increases in intracellular calcium concentrations
[Ca2+]i via the activation of either inositol-3 phosphate
receptors (IP3Rs) store-operated channels, or by directly
interacting with voltage-gated Cav1.3 Ca
2+ channel (Park
et al. 2010; New et al. 2006; Meier et al. 2008). Therefore,
we investigated the possibility that the aforementioned
allosteric ligands can modulate GABABR-mediated
increases in intracellular Ca2+ levels in the HEKHGBR and
the CHORGBR cells. As expected, addition of GABA
induced a rise in [Ca2+]i within 20–30 sec of GABA addi-
tion, reaching a maximal response at 45–50 sec after
agonist addition, before returning to basal levels within
120 sec (data not shown).
As shown in Figures 5–7, addition of GABA resulted in
a concentration-dependent increase in [Ca2+]i with an
EC50 value of 1.4 and 0.25 lmol/L in the CHORGBR and
HEKHGBR cells, respectively. These EC50 values correlate
well with EC50 values obtained in the cAMP HTRF assay.
The GABA-induced Ca2+ response was abolished by co-
treatment with the competitive antagonist CGP54626 in a
concentration-dependent manner and no response to
GABABR agonists was observed in the parental CHO and
HEK cell lines (data not shown).
In the CHORGBR cell line, 1, 5, and 10 lmol/L of
GS39783, decreased GABA potency by two-, three-, and
sixfold, respectively (Fig. 5A; Table 2). Similarly, in
HEKHGBR cells, GABA EC50 was decreased by threefold in
the presence of 0.1 and 0.5 lmol/L of GS39783 and by
4–5 fold when the allosteric ligand was present at higher
concentrations (Fig. 5B; Table 2). Thus, with regard to
changes in [Ca2+]i, GS39783 decreases GABA potency
Figure 4. cAMP HTRF-measured effects of NVP998 on GABA-induced GABABR-mediated inhibition of forskolin-stimulated cAMP production.
Concentration–response curves for GABA in the absence and in the presence of increasing concentration of allosteric ligand in CHORGBR (A),
HEKHGBR (B), or CHOHGBR (C) cells line. (D) Linear regression plots were constructed from the logarithm of NVP998 concentration against the
logarithm of the fold shift of the GABA EC50 (a). The solid and dashed trendlines were created by plotting the a values obtained with NVP998 at
0.1–1 lmol/L or 0.1–10 lmol/L, respectively. The data are means  SEM of a typical experiment that was performed three times.
ª 2017 The Authors. Pharmacology Research & Perspectives published by John Wiley & Sons Ltd,
British Pharmacological Society and American Society for Pharmacology and Experimental Therapeutics.
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and as such behaves as a negative allosteric modulator
(NAM) in both cell lines. Interestingly, in the absence of
GABA, addition of 5 and 10 lmol/L of GS39783 induced
a rise in [Ca2+]i in both cellular systems (~23% and
~60%, respectively) (Fig. 5A and B; Table 2). However,
similar activity was also observed in parental CHO and
HEK293 cells suggesting that the GS39783-induced rise in
[Ca2+]i is not GABABR specific (data not shown). As
observed in the cAMP assay (Fig. 2D), correlation plots
constructed from the fold shift of the GABA EC50 (a) in
the presence of a given concentration of the modulator
demonstrated that GS39783 in vitro NAM activity was
comparable in CHORGBR and HEKHGBR cells (Fig. 5C,
Table 3). Nevertheless, low micromolar concentration
(0.1–1 lmol/L) only exhibited significant NAM activity
with P = 0.0009 (F-test from nonzero slope) in cells
expressing the human GABABR heterodimer (HEKHGBR)
(Fig. 5C, Table 3). Thus, together with the cAMP assay
data, these observations suggest that GS39783 displays sig-
naling pathway-specific activity.
In the CHORGBR cells, BHF177 at 10 lmol/L was found
to exhibit PAM activity (a = 4) as well as some degree of
intrinsic activity (12  3%), whereas lower concentrations
did not significantly affect GABABR-mediated changes in
[Ca2+]i (Fig. 6A, Table 2). Conversely, in the HEKHGBR
cells, BHF177 at 0.1–5 lmol/L exhibited weak negative
allosteric modulator (NAM) activity as indicated by a right-
ward shift of the GABA CRC (Fig. 6B; Table 2). Neverthe-
less, correlation plots constructed from the fold shift of the
GABA EC50 (a) in the presence of a given concentration of
the modulator demonstrated that with regard to [Ca2+]i
mobilization, BHF177 does not exhibit significant PAM/
NAM activity in cellular systems expressing either the rat or
the human GABABR heterodimer (Fig. 2D, Table 3). These
data indicate that BHF177 has differential effects on
GABABR-mediated changes in intracellular calcium levels
versus cAMP levels suggesting that BHF177 not only exhi-
bits species selectivity but also pathway-selective behavior.
In the CHORGBR cell line, 0.1, 0.5, and 1 lmol/L of
NVP998 decreased GABA potency by three-, four-, and
sixfold, respectively (Fig. 7A; Table 2). In contrast, at 5
and 10 lmol/L, the allosteric ligand exhibited PAM activ-
ity and enhanced GABA potency by 2–3 fold. The correla-
tion plot constructed from the fold shift of the GABA
EC50 (a) in the presence of a given concentration of the
modulator demonstrated that at low micromolar concen-
trations NVP998 exhibits significant NAM activity with
P = 0.0001 (F-test from nonzero slope) in cells expressing
the rat GABABR receptor (Fig. 7C, Table 3). These
in vitro observations correlate well with the absence of an
in vivo effect of NVP998 on nicotine self-administration
(Fig. 1). In HEKHGBR cells, NVP998 at 10 lmol/L exhib-
ited PAM activity (a = 3) (Fig. 7B; Table 2) and
displayed intrinsic agonist activity (~20%). In contrast,
lower concentrations of the allosteric ligand did not affect
GABABR activity in this cellular assay system.
Effects of GS39783 and analogs on GABABR-
mediated ERK1/2 phosphorylation
It has been reported that GABABR activation leads to the
activation of the ERK1/2 signaling cascade. ERK1/2 activa-
tion occurs via the GABABR2 subunit coupling to Gi/o
proteins by releasing the Gbc subunit (Tu et al. 2007). In
addition, a recent report indicated that the GABABR can
increase ERK1/2 phosphorylation by directly interacting
with, and activating the Ca(v)1.3 channel (Im and Rhim
2012). Thus, we next investigated the possibility that the
allosteric ligands would also modulate GABABR-mediated
ERK1/2 phosphorylation. We first studied the effect of a
saturating concentration of GABA (100 lmol/L) on
ERK1/2 phosphorylation in the CHORGBR and HEKHGBR
cells using the “In cell” western blot technique to deter-
mine the time point at which maximal ERK1/2 phospho-
rylation occurs after receptor activation. Addition of
GABA induced a rapid and transient increase in ERK1/2
phosphorylation peaking at 5 min, with no changes in
total ERK1/2 expression in both cellular systems (Fig. S1).
Importantly, no response to the GABABR agonist was
observed in the parental CHO or HEK293 cell line (data
not shown).
To investigate the effect of the allosteric ligands on
GABABR-mediated ERK1/2 activation, both cellular sys-
tems were stimulated with GABA alone or in the presence
of the modulator for 5 min, and ERK1/2 phosphorylation
was measured using Cellul’erk HTRF assay. As antici-
pated, addition of GABA resulted in a concentration-
dependent increase in phospho-ERK with an EC50 value
of 0.56 lmol/L and 0.65 lmol/L in CHORGBR and
HEKHGBR cells, respectively (Fig. 8). We next investigated
the effect of the allosteric ligands on GABABR-mediated
ERK1/2 phosphorylation.
In CHORGBR cells, 1 lmol/L GS39783 alone did not
promote ERK1/2 phosphorylation, whereas it enhanced
GABA potency by fivefold when present at 10 lmol/L
(Fig. 8A; Table 2). In addition, in this cellular system, the
maximal stimulation obtained by saturating concentra-
tions of GABA was significantly increased in the presence
of 1 and 10 lmol/L of the allosteric ligand (~120%)
(Fig. 8A; Table 2). In HEKHGBR cells, GS39873 enhanced
GABA potency by two- and eightfold and exhibited sig-
nificant intrinsic activity, activating ERK1/2 by 52%  7
and 63%  14 when present at 1 and 10 lmol/L, respec-
tively (Fig. 8D, Table 2). In the CHORGBR cells, 1 and
10 lmol/L of BHF177 enhanced GABA potency by two-
and threefold, respectively (Fig. 8B; Table 2). Also, the
2017 | Vol. 5 | Iss. 2 | e00288
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Table 3. Linear regression analyses comparing the logarithm of the allosteric ligand concentration against the logarithm of the fold shift of the
GABA EC50 (a) to predict PAM activity of GS39783 and analogs in CHORGBR, CHOHGBR, or HEKHGBR, cells. Linear regression analyses were also
performed with in vivo relevant dose of the different PAMs (0–1 lmol/L).
Assay Cell line (drug) (lmol/L)
GS39783 BHF177 NVP998
Slope P Slope P Slope P
cAMP
assay
CHORGBR 0–1 0.1143  0.0107 0.0018* 0.1637  0.0059 0.0001* – –
0–10 0.1440  0.0166 0.0003* 0.1805  0.0069 <0.0001* 0.0382  0.0248 0.1855
CHOHGBR 0–1 0.1804  0.0185 0.0023* – – 0.2267  0.0386 0.0099*
0–10 0.1808  0.0189 0.0002* 0.0482  0.0314 0.1855 0.2071  0.0260 0.0005*
HEKHGBR 0–1 0.1403  0.0125 0.0015* – – 0.1340  0.0386 0.0403*
0–10 0.1952  0.0227 0.0004* 0.0382  0.0248 0.1855 0.1620  0.0273 0.0019*
Calcium
assay
CHORGBR 0–1 0.0445  0.0287 0.2196 0.0426  0.0728 0.6176 0.2422  0.0093 0.0001*
0–10 0.1157  0.0319 0.0152* 0.1190  0.0606 0.1214 0.0389  0.0758 0.6298
HEKHGBR 0–1 0.2139  0.0160 0.0009* 0.1316  0.0477 0.1104 – –
0–10 –0.1796  0.0151 <0.0001* –0.0349  0.0640 0.6146 0.0382  0.0248 0.1855
ERK
assay
CHORGBR 0–1 – – 0.1003 – – –
0–10 0.1118  0.05931 0.2 0.1125  0.0064 0.0033* 0.0763  0.0404 0.2
HEKHGBR 0–1 0.1003  0.0 – 0.233 – 0.233 –
0–10 0.1806  0.04257 0.0513 0.1957  0.0197 0.0101* 0.1957  0.0197 0.0101*
*Significant deviation from zero (F-test for non-zero slope, P-value).
Figure 5. Potentiation of GABA-induced GABABR-mediated intracellular calcium mobilization by GS39783. Concentration–response curves for
GABA in the absence or presence of increasing concentrations of allosteric ligand in CHORGBR (A) or HEKHGBR (B) cell lines. (C) Linear regression
plots were constructed from the logarithm of GS39783 concentration against the logarithm of the fold shift of the GABA EC50 (a). The solid and
dashed trendlines were created by plotting the a values obtained with GS39783 at 0.1–1 lmol/L or 0.1–10 lmol/L, respectively. The data are
means  SEM of a typical experiment that was performed three times.
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maximal stimulation obtained by a saturating concentra-
tion of GABA was significantly increased in the presence
of 10 lmol/L of BHF177 (117%  7). In HEKHGBR cells,
BHF177 enhanced GABA EC50 by fivefold at 1 and
10 lmol/L, and also displayed significant intrinsic activity
at the highest concentration (30%  6) (Fig. 8E;
Table 2).
In the CHORGBR cells, NVP998 did nor enhance GABA
potency at 1 lmol/L, whereas the allosteric ligand
enhanced GABA EC50 by threefold at 10 lmol/L (Fig. 5C,
Table 2). In this cellular system, NVP998 also displayed
significant intrinsic activity at 10 lmol/L and activated
ERK1/2 by 20%  1 (Fig. 5C, Table 2). In addition, as
observed with the other allosteric ligands, the maximal
stimulation obtained by saturating concentrations of
GABA was significantly increased in the presence of 1 and
10 lmol/L of NVP998 (~130%) (Fig. 5C, Table 2). In
HEKHGBR cells, 1 and 10 lmol/L of NVP998 enhanced
GABA EC50 by fivefold, and exhibited significant intrinsic
activity (44%  6 and 51%  5, respectively) (Fig. 8F;
Table 2). Correlation plots constructed from the fold shift
of the GABA EC50 (a) in the presence of a given
concentration of the modulator demonstrated that with
regard to ERK activation, (i) BHF177 displays significant
PAM activity in both CHORGBR and HEKHGBR with
P = 0.0033 and 0.0101 (F-test from nonzero slope),
respectively, (ii) NVP998 exhibits significant PAM activity
only in HEKHGBR with P = 0.010 (F-test from nonzero
slope), and (iii) GS39783 did not demonstrate significant
PAM activity in these cellular systems (Fig. 8G, Table 3).
Together with our previous observations these data con-
firm that GABABR allosteric ligands not only exhibit
functional selectivity but their activities are also context-
dependent.
Effects of GS39783 and analogs on GABABR
desensitization
Since the allosteric ligands display intrinsic activity, they
may induce GABABR desensitization. Thus, we further
investigated the effect of GS39783, BHF177 and
NVP998 on GABABR desensitization using a label free
technology (CellKey system) which allows noninvasive
bioimpedance-based measurement of an integrated
Figure 6. Potentiation of GABA-induced GABABR-mediated intracellular calcium mobilization by BHF177. Concentration–response curves for
GABA in the absence or presence of increasing concentrations of allosteric ligand in CHORGBR (A) or HEKHGBR (B) cell lines. (C) Linear regression
plots were constructed from the logarithm of BHF177 concentration against the logarithm of the fold shift of the GABA EC50 (a). The solid and
dashed trendlines were created by plotting the a values obtained with BHF177 at 0.1–1 lmol/L or 0.1–10 lmol/L, respectively. The data are
means  SEM of a typical experiment that was performed three times.
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cellular response (Ciambrone et al. 2004). In this assay,
GABA induced concentration-dependent changes in cel-
lular impedance with an EC50 value of 0.57 lmol/L in
CHORGBR. In agreement with our previous data, the
allosteric ligands exhibited PAM activity and displayed
intrinsic activity when present at 10 lmol/L (Fig. 9A–C,
Table 2). It is well established that following a first
stimulation, GPCRs that undergo desensitization display
reduced responsiveness to a second stimulation with an
agonist. Therefore, CHORGBR cells were stimulated for
20 min with 1 or 10 lmol/L of the allosteric ligands,
or 1 or 100 lmol/L of the orthosteric agonist GABA.
Subsequently, the ligand-containing medium was
removed; the cells were washed three times and further
incubated in assay buffer for 30 min before being stim-
ulated a second time with a GABA EC90 (~5 lmol/L).
In CHORGBR cells exposed to 100 lmol/L of GABA, the
response to a second stimulation was significantly atten-
uated (Fig. 9D). In good agreement with previous
reports (Gjoni and Urwyler 2008), these data suggest
that high concentrations of GABA induce GABABR
desensitization. In contrast, in CHORGBR cells exposed
to the allosteric ligands, the variation of cellular impe-
dance induced by the second stimulation was not
decreased when compared to the control (Fig. 9E) sug-
gesting that the allosteric ligands do not promote
GABABR desensitization.
Discussion
In this study, we have performed extensive in vitro phar-
macological characterization of the structurally related
GABABR-positive allosteric modulators (PAMs), GS39783,
BHF177, and NVP998. We have also examined the effects
of NVP998 on nicotine self-administration in the rat in
order to compare these effects to our previously published
data describing the effects of GS39783, and BHF177 on
nicotine self-administration (Paterson et al. 2008; Vlachou
et al., 2011). The main findings are that each of the
GABABR allosteric ligands evaluated exhibit functional as
well as receptor ortholog selectivity, indicating that even
minor structural changes can have profound effects on
Figure 7. Potentiation of GABA-induced GABABR-mediated intracellular calcium mobilization by NVP998. Concentration–response curves for
GABA in the absence or presence of increasing concentrations of allosteric ligand in CHORGBR (A) or HEKHGBR (B) cell line. (C) Linear regression
plots were constructed from the logarithm of NVP998 concentration against the logarithm of the fold shift of the GABA EC50 (a). The solid and
dashed trendlines were created by plotting the a values obtained with NVP998 at 0.1–1 lmol/L or 0.1–10 lmol/L, respectively. The data are
means  SEM of a typical experiment that was performed three times.
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pathway and species selectivity; critical properties that
need to be considered as early as possible in the drug
discovery process.
A decade ago GS39783, and structural analogs BHF177,
and NVP998, were the first positive allosteric modulators
(PAMs) of the GABABR to be described. These molecules
were found to potentiate GABA-stimulated guanosine 50-
O-(3-[(35)S]thiotriphosphate) ([35S]GTPcS) binding to
membranes generated from CHO cells heterologously
expressing the human/rat GABABR (CHORGBR),
exhibiting maximal effect at 10 lmol/L (Urwyler et al.
2003; Guery et al. 2007). More recently, we have demon-
strated that BHF177 and GS39783 are effective in decreas-
ing nicotine self-administration in rats (Paterson et al.
2008). Interestingly, the in vivo efficacy of GS39783 was
equivalent to BHF177 only when co-administered with a
subeffective dose of the GABABR agonist CGP44532.
Here, we demonstrate that NVP998 when administered
either p.o or i.c.v had no effect on nicotine self-adminis-
tration under fixed- and progressive-ratio schedules of
Figure 8. Modulation of GABABR-mediated ERK1/2 phosphorylation by GS39783 and analogs. The graphs A–F show representative
concentration–response curves for GABA in the Cellul’erk HTRF assay either in the absence or in the presence of 1 or 10 lmol/L of the specified
allosteric ligand. The data points are normalized to the maximal effect of GABA alone. The responses were measured in either CHORGBR (A, C,
and E) or HEKHGBR (B, D, F) cell lines. (G) Linear regression plots were constructed from the logarithm of the allosteric ligand concentration
against the logarithm of the fold shift of the GABA EC50 (a). The solid and dashed trendlines were created by plotting the a values obtained with
allosteric ligand at 0–1 lmol/L or 0–10 lmol/L, respectively. The data are means  SEM of a typical experiment that was performed three times.
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reinforcement, suggesting that this compound had no
effect on the reinforcing and motivational aspects of self-
administered nicotine. Thus, despite the structural simi-
larities, reported in vitro PAM activity (Urwyler et al.
2001), equivalent oral bioavailability, and similar brain
exposure (Table 1), these GABABR PAMs exhibit distinct
in vivo efficacies.
It is now well accepted that different ligands acting at
the same receptor subtype can activate/modulate distinct
patterns of downstream responses, a phenomenon
referred to as “functional selectivity”, or “ligand bias”.
With this in mind and as the GABABR possesses pleiotro-
pic signaling capacity (Bettler and Tiao 2006), we hypoth-
esized that differences in GABABR allosteric modulator
behavior toward specific signaling pathways may account
for the dissimilarities observed in their efficacy in rat
model of nicotine addiction. To test this hypothesis, we
characterized the in vitro pharmacological profile of
GS39783, BHF177, and NVP998 by investigating their
effect on GABA-induced GABABR-mediated; (i) changes
in intracellular cAMP levels; (ii) [Ca2+]i mobilization; and
(iii) ERK1/2 phosphorylation. Since we used the rat as a
preclinical model, and GS39783, BHF177, and NVP998
have previously been demonstrated to bind to the trans-
membrane domain of the GABABR2 subunit (Binet et al.
2004), we used CHORGBR cells expressing the human
GABABR1b and the rat GABABR2 subunits. Importantly,
the GABA half-maximal response (EC50) values obtained
in the three distinct cell-based functional assays were
found to correlate well with those previously reported in
the literature (Urwyler et al. 2001). In good agreement
with previous reports, 10 lmol/L of GS39783, BHF177,
and NVP998 increased GABA potency in the cAMP assay
performed with CHORGBR (Urwyler et al. 2003; Guery
et al. 2007). Importantly, in this assay, BHF177 and
GS39783 also displayed significant PAM activity at con-
centrations found in the rat brain (0.1–1 lmol/L),
enhancing GABA EC50 by 2–3 fold (Table 3). In contrast,
NVP998, did not demonstrate PAM activity at similar
concentrations. Furthermore, GS39783 and BHF177 also
exhibited significant intrinsic agonist activity in this assay
(Fig. 2; Table 2), whereas NVP998 did not demonstrate
Figure 9. Characterization of GABABR PAM effects on receptor desensitization using the CellKey assay. Concentration–response curves for GABA
in the absence or presence of GS39783 (A), BHF177 (B) and NVP998 (C) in CHORGBR. D, Concentration–response curves for GABA in the absence
or presence of increasing concentrations of allosteric ligand in CHORGBR (A) or HEKHGBR (B) cell line. (C) Effect of GS39783, BHF177, and NVP998
on GABABR desensitization. The data are means  SEM of a typical experiment that was performed three times.
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ago-allosteric modulator activity. Interestingly, the
CellKey assay data revealed that in contrast to the orthos-
teric agonist, the allosteric ligands can activate the
GABABR without inducing receptor desensitization, a
phenomenon involved in the development of tolerance.
The [Ca2+]i mobilization assay revealed additional differ-
ences in the behavior of the allosteric ligands in the
CHORGBR cells. Indeed, in this assay, low micromolar
concentrations of GS39783 and BHF177 did not signifi-
cantly affect GABA potency, whereas low micromolar
concentrations of NVP998 displayed significant NAM
activity resulting in a decrease in GABA EC50. Finally, in
the ERK1/2 activation assay, low micromolar concentra-
tions (0.1–1 lmol/L) of GS39783 and NVP998 did not
affect GABA potency, whereas BHF177 displayed PAM
activity.
These results suggest that GABABR allosteric ligands
might exhibit distinct pathway-specific activity, highlight-
ing the complexity of allosteric ligand behavior. Further-
more, these in vitro data indicate that in contrast to
GS39783 and BHF177, NVP998 at the concentrations we
observed in the rat brain, do not enhance GABA-induced
cAMP nor ERK signaling and negatively modulated the
GABA-mediated increase in [Ca2+]i. Together with our
pharmacokinetics data, the NVP998 in vitro pharmaco-
logical profile in the CHORGBR cell line may explain the
absence of effects on nicotine self-administration in rat.
Thus, when comparing the in vitro profile of GS39783
and its analogs to their in vivo efficacy, our results sug-
gest that allosteric ligands displaying an in vitro pharma-
cological profile similar to BHF177 may represent
compounds that would be predicted to exhibit the desired
in vivo properties.
In addition to functional selectivity, our studies also
revealed that, GS39783, BHF177, and NVP998 may exhi-
bit species-specific pharmacology. This characteristic has
been previously described for numerous GPCR ligands
including those that modulate adrenergic receptors, his-
tamine receptors and GPR35 (Jenkins et al. 2012; Neetoo-
Isseljee et al. 2013) as well as for allosteric modulators of
the mGluR1 receptor, another family C GPCR (Knoflach
et al. 2001). In agreement with previous reports demon-
strating the effects of GS39783 in rat versus human
GABABR cellular systems (Urwyler et al. 2003), we found
that this allosteric ligand displays similar efficacy in the
cAMP assay in CHORGBR, in CHOHGBR, and in HEKHGBR
cells. On the other hand, BHF177 and NVP998 both dis-
played species-specific behaviors. Indeed, in the cAMP
assay, low micromolar concentrations (0.1–1 lmol/L) of
BHF177 increased GABA potency in the CHORGBR but
not in the CHOHGBR nor in HEKHGBR cells. Interestingly,
in the same assay, NVP998 displayed alternate species-
selectivity. Indeed, NVP998 enhanced GABA EC50 at low
micromolar concentrations and exhibited strong intrinsic
activity in CHOHGBR and HEKHGBR cells, whereas its ago-
PAM activity was only observed at the highest concentra-
tion tested in the CHORGBR. Importantly, as noted above,
the in vitro activity profile of these compounds together
with their in vivo plasma and brain levels correlates well
with their efficacy (BHF177), or lack thereof (NVP998) in
a rat model of nicotine dependence. Since the in vitro
pharmacological profile of NVP998 at the human receptor
is comparable to that of BHF177 at the rat receptor, it
may still represent a useful molecule for the development
of GABABR-targeted therapy for nicotine addiction. How-
ever, in order for a molecule like NVP998 to progress in
the drug development process, it would require evaluation
in an alternative preclinical model such as nonhuman pri-
mates (Le Foll et al.; 2007), assuming species-selectivity is
not an issue.
In conclusion, our studies demonstrate that func-
tional and species-selectivity are operational at a
GABABR allosteric site, and that these phenomena have
profound implications for drug discovery targeting the
GABABR. Therefore, significant consideration must be
given in the selection of appropriate ligands to progress
in the drug discovery and development process. Impor-
tantly, we show that in vitro pharmacological profiling
of GABABR allosteric ligands can be predictive of
in vivo efficacy in a preclinical rat model of nicotine
addiction. Hence, parallel screening against receptor
orthologs (human and preclinical model species) using
a multi cell-based assay platform provides an ideal
framework for selecting compounds with therapeuti-
cally appropriate profiles and will help bridge the gap
between in vitro and in vivo compound efficacy.
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